ArticleInfection and immunity2009
Protection against intestinal amebiasis by a recombinant vaccine is transferable by T cells and mediated by gamma interferon.
Article in Infection and immunity, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 49 citations in OpenAlex.
- Immunogenicity and safety of anHuman vaccines & immunotherapeutics · 2024Article
- Host Protective Mechanisms to Intestinal Amebiasis.Trends in parasitology · 2021Review
- Optimizing a Multi-Component IntranasalFrontiers in immunology · 2021Article
- Evaluation of the PEJournal of immunology research · 2021Article
- Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine forNPJ vaccines · 2018Article
- Nanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica.Vaccine · 2017Article
- Immune responses against protozoan parasites: a focus on the emerging role of Nod-like receptors.Cellular and molecular life sciences : CMLS · 2016Review
- Evaluation of the C-Terminal Fragment of Entamoeba histolytica Gal/GalNAc Lectin Intermediate Subunit as a Vaccine Candidate against Amebic Liver Abscess.PLoS neglected tropical diseases · 2016Article
- Immune Response of Amebiasis and Immune Evasion by Entamoeba histolytica.Frontiers in immunology · 2016Review
- Chew on this: amoebic trogocytosis and host cell killing by Entamoeba histolytica.Trends in parasitology · 2015Review
- Entamoeba histolytica: adhesins and lectins in the trophozoite surface.Molecules (Basel, Switzerland) · 2015Review
- Protection against Amoebic Liver Abscess in Hamster by Intramuscular Immunization with an Autographa californica Baculovirus Driving the Expression of the Gal-Lectin LC3 Fragment.BioMed research international · 2015Article
- Expression, purification, and evaluation of recombinant LecA as a candidate for an amebic colitis vaccine.Vaccine · 2014Article
- Regulation of virulence of Entamoeba histolytica.Annual review of microbiology · 2014Review
- Host immune response to intestinal amebiasis.PLoS pathogens · 2013Review
- The dynamic interdependence of amebiasis, innate immunity, and undernutrition.Seminars in immunopathology · 2012Review
- Evidence of gene conversion in genes encoding the Gal/GalNac lectin complex of Entamoeba.PLoS neglected tropical diseases · 2011Article
- Leptin signaling in intestinal epithelium mediates resistance to enteric infection by Entamoeba histolytica.Mucosal immunology · 2011Article
- CD4+ and CD8+ T cell- and IL-17-mediated protection against Entamoeba histolytica induced by a recombinant vaccine.Vaccine · 2011Article
- Vaccines to combat the neglected tropical diseases.Immunological reviews · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
We have previously shown that vaccination with purified Entamoeba histolytica Gal/GalNAc lectin or recombinant subunits can protect mice from intestinal amebiasis upon intracecal challenge. In this study, we demonstrated with adoptive-transfer experiments that this lectin vaccine protection is mediated by T cells but not serum. The cell-mediated immune (CMI) response was characterized by significant gamma interferon (IFN-gamma), interleukin 12 (IL-12), IL-2, IL-10, and IL-17 production. To move toward a human vaccine, we switched to a recombinant protein and tested a range of adjuvants and routes appropriate for humans. We found that subcutaneous delivery of LecA with IDRI's adjuvant system EM014 elicited a potent Th1-type CMI profile and provided significant protection, as measured by culture negativity (79% efficacy); intranasal immunization with cholera toxin provided 56% efficacy; and alum induced a Th2-type response that protected 62 to 68% of mice. Several antibody and CMI cytokine responses were examined for correlates of protection, and prechallenge IFN-gamma(+) or IFN-gamma-, IL-2-, and tumor necrosis factor alpha-triple-positive CD4 cells in blood were statistically associated with protection. To test the role of IFN-gamma in LecA-mediated protection, we neutralized IFN-gamma in LecA-immunized mice and found that it abrogated the protection conferred by vaccination. These data demonstrate that CMI is sufficient for vaccine protection from intestinal amebiasis and reveal an important role for IFN-gamma, even in the setting of alum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.